NCT04064840View on ClinicalTrials.gov

GnRH Agonist for Dual Trigger in IVF and for Luteal Phase Support in FET

PHASE3RecruitingINTERVENTIONAL
Enrollment

784

Participants

Timeline

Start Date

September 1, 2019

Primary Completion Date

September 1, 2024

Study Completion Date

March 30, 2025

Conditions
Subfertility
Interventions
DRUG

IVF: Decapeptyl and hCG

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and decapeptyl 0.2mg will be injected subcutaneously.

DRUG

FET: Decapeptyl

On the day of FET, decapeptyl 0.1 mg will be injected subcutaneously.

DRUG

IVF: hCG and normal saline

When at least three follicles reach 18 mm in diameter, recombinant hCG 0.25mg and normal saline will be injected subcutaneously.

DRUG

FET: Normal Saline

On the day of FET, normal saline will be injected subcutaneously.

Trial Locations (1)

Unknown

RECRUITING

Department of Obstetrics and Gynaecology, Hong Kong

All Listed Sponsors
lead

The University of Hong Kong

OTHER